- Vaccine Name: WT1 Trio Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: WT1(Oji et al., 2023)
- Preparation: Recombinant protein preparation
- Immunization Route: Intramuscular injection (i.m.)
- Description: This vaccine is for cancers that express WT1, including malignant glioma, soft tissue sarcoma, malignant pleural mesothelioma, thymic cancer, and other rare cancers (i.e., testicular cancer, salivary gland cancer, olfactory neuroblastoma). The WT1 Trio Peptide Vaccine (WT1-235, WT1-126, WT1-332) significantly increased IgG antibody levels for all three peptides, demonstrating robust humoral immune responses. WT1 Trio induced stronger antibody responses than the single WT1-235 peptide vaccine. (62.9% of WT1 Trio-treated patients showed positive DTH reactions, comparable to those treated with WT1-235 alone.) 33.3% (15 out of 45) of patients achieved stable disease after 3 months of vaccination. SD rates were highest in malignant pleural mesothelioma (50%), malignant glioma (40%), and soft tissue sarcomas (25%). (Oji et al., 2023)
|
